原发中枢神经系统淋巴瘤疾病进展与生存的基因组生物标志物鉴定
研究对78例接受标准甲氨蝶呤方案治疗的初诊原发中枢神经系统淋巴瘤(PCNSL)患者诊断标本行靶向二代测序,发现4个位点的基因组异常与91%的淋巴瘤进展事件及全部15例死亡相关,Cox回归多因素分析显示这些位点异常患者进展风险高、生存显著缩短,HLA-DR低表达与6p拷贝中性杂合性缺失(CN-LOH)/6p21.3纯合缺失(HD)及不良预后相关。
要点
- 4个位点基因组异常与91%的进展事件及全部15例死亡相关。
- 6p CN-LOH或6p21.3 HD、BTG1、ETV6、TP53异常提示高进展风险。
- HLA-DR低表达与6p CN-LOH/6p21.3 HD及不良预后相关。
核心结论
- 这些基因组异常识别出一个高风险分子亚组,可能有助于PCNSL的风险分层。
- 进一步阐明与高风险遗传表型相关的治疗耐药机制是推进精准医学和治疗进展所必需的。
研究设计与样本
- 对78例接受标准甲氨蝶呤方案治疗的PCNSL患者诊断标本行靶向二代测序,检测复发性单核苷酸变异、拷贝数改变及接合性异常。
- 所有患者接受诱导免疫化疗,其中44例进入剂量密集型巩固治疗。
主要发现
- 4个位点的基因组异常与91%的淋巴瘤进展事件及全部15例死亡相关。
- 4个位点分别为:6p拷贝中性杂合性缺失(CN-LOH)或6p21.3局灶性纯合缺失(HD),以及抑癌基因BTG1、ETV6和TP53突变。
- Cox回归多因素分析显示这些位点异常患者进展风险高。
- 这些位点基因组异常亦与生存期显著缩短相关。
- HLA-DR低表达与6p CN-LOH/6p21.3 HD及不良预后相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The determination of the genetic subtypes of primary central nervous system lymphoma (PCNSL) and their relationship to differential chemoimmunotherapeutic response has not been established. There is a particular need for genomic biomarkers that identify patients with newly diagnosed PCNSL at high risk of early progression and death. We applied targeted next-generation sequencing for detection of recurrent single-nucleotide variants, copy number alterations, and zygosity abnormalities in diagnostic specimens from 78 patients with PCNSL treated with a standard methotrexate-based regimen, to identify prognostically significant molecular subgroups. All patients received induction immunochemotherapy, and 44 proceeded to dose-intensive consolidation. Genomic aberrations at 4 loci were associated with 91% of lymphoma progression events and all 15 deaths: (1) chromosome 6p copy-neutral loss of heterozygosity (CN-LOH) or focal homozygous deletion (HD) at 6p21.3, and mutations of tumor suppressor genes (2) BTG1, (3) ETV6, and (4) TP53. Cox regression multivariate analysis demonstrated a high risk of progression in patients with aberrations at these loci. Genomic aberrations at these loci were also associated with significantly shorter survival. Lower expression of HLA-DR was associated with 6p CN-LOH/6p21.3 HD and inferior prognosis. These genomic aberrations identify a high-risk molecular subgroup that may inform risk stratification in PCNSL. Further elucidation of the mechanisms of therapeutic resistance associated with the high-risk genetic phenotype is requisite to facilitate precision medicine and progress in therapy.
引用
- Geng H, Mo S, Chen L, et al. Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma. Blood Adv. 2025. PMID: 39536287. doi:10.1182/bloodadvances.2024014460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。